Mednotes

L10 Metabolism Metabolic syndrome

Properties2
tagsmetabolism, lecture, endocrinology
aliasesIntroduction to Metabolic Syndrome

17 min read

Overview

This lecture introduces the metabolic syndrome: what it is, how its diagnostic definition has evolved and still varies between bodies (IDF, WHO, “harmonized”), how common it is and how prevalence changes with age and ethnicity, why the diagnosis matters clinically, and the definitional controversies (particularly around central obesity and the circularity of including type 2 diabetes as a criterion). It then covers the proposed pathophysiology linking central/visceral obesity to chronic inflammation and insulin resistance, and from there to diabetes, cardiovascular disease and other organ damage, before covering associated conditions, the newer CKM (cardiovascular-kidney-metabolic) model, and management from lifestyle through pharmacotherapy to bariatric surgery.

Definition of Metabolic Syndrome

Metabolic syndrome is a cluster of abnormalities that often occur together and are associated with increased risk of type 2 diabetes and cardiovascular disease. Multiple slightly different definitions exist — more alike than different — and have evolved over time, with additional conditions periodically linked to the syndrome. No single cause has been identified, but several contributing causes are agreed upon. Discussion of the syndrome has been clinically useful, though parts of the definition remain controversial.

IDF definition (2006, updated 2009):

  • Central adiposity (per ethnicity-specific data) — assumed present if BMI >30 kg/m²
  • Plus any two of:
    • Raised triglycerides >1.7 mmol/L, or treatment for this
    • Reduced HDL cholesterol (<1.0 mmol/L males, <1.3 mmol/L females), or treatment
    • Raised blood pressure (systolic >130 mmHg, diastolic >85 mmHg), or treatment for hypertension
    • Raised fasting plasma glucose >5.6 mmol/L, or type 2 diabetes

A second IDF (2006) slide in the source gives slightly different BP thresholds (systolic >135, diastolic >80 mmHg) rather than the >130/85 used in the “updated 2009” version above; both are recorded as presented in the slides, not reconciled.

WHO definition (1998):

  • One of: type 2 diabetes, raised fasting glucose, insulin resistance, or impaired glucose tolerance
  • Plus two of:
    • Blood pressure >140/90 mmHg
    • Dyslipidaemia: TG >1.7 mmol/L, HDL <0.9 mmol/L (male), <1.0 mmol/L (female)
    • Central obesity: waist:hip ratio >0.90 (male), >0.85 (female), or BMI >30 kg/m²
    • Microalbuminuria

“Harmonized” criteria (2009 update, Alberti et al.):

MeasureCut point
Elevated waist circumferencePopulation- and country-specific
Elevated triglycerides≥1.7 mmol/L
Low HDL-CMen <1.0 mmol/L; women <1.3 mmol/L
Elevated blood pressureSystolic ≥130 and/or diastolic ≥85 mmHg
Elevated fasting glucose≥100 mg/dL (5.5 mmol/L)

Ethnicity/region-specific waist-circumference cut-offs (Alberti et al., 2009):

  • Europid, sub-Saharan African, Eastern Mediterranean/Middle Eastern: men >94 cm, women >80 cm
  • South Asian, Chinese, South/Central American: men >90 cm, women >80 cm
  • Japanese: men >85 cm, women >90 cm

A broader regional/ethnic table (Neeland et al., 2024) gives BMI and waist-circumference thresholds for obesity/overweight by country, e.g.: most North American/European countries (BMI obesity 30.0, overweight 25.0; WC men 102 cm/women 88 cm); China (28.0/24.0; 90/85 cm); Japan (25.0/–; 85/90 cm); Māori and Pacific Islanders (32.0/26.0; 102/88 cm). Other countries/regions listed with their own cut-offs include Malaysia, Singapore, Taiwan, India, Republic of Korea, Philippines, Sri Lanka, Hong Kong SAR, Bangladesh, Thailand, Vietnam, Tunisia, Iran, sub-Saharan Africa, and the Eastern Mediterranean/Middle East [full country-by-country values given only in the source table].

History

The idea that a phenotype links diabetes and heart disease is not new:

  • 1921 — Joslin noted type 2 diabetes correlated with weight.
  • 1923 — Kylin found a correlation between high blood pressure, high glucose, and gout.
  • 1947 — Vague found upper-body obesity predisposes to cardiovascular disease and type 2 diabetes.
  • 1977 — Haller and Singer used “metabolic syndrome” to describe varying combinations of these conditions, also including hyperuricaemia/gout and fatty liver disease.
  • 1988 — Reaven proposed insulin resistance as the causative factor and coined the term “Syndrome X” (Banting Lecture, cited 14,867 times); Syndrome X comprised resistance to insulin-stimulated glucose uptake, glucose intolerance, hyperinsulinaemia, increased VLDL triglyceride, decreased HDL cholesterol, and hypertension.
  • 2005 — Eckel, Grundy and colleagues proposed central obesity (visceral fat) and associated inflammation as the key cause.
  • 2023 — Newer CKM (cardiovascular-kidney-metabolic) model proposed, with renal inclusion and broader connections.

Slide 9 shows a scanned historical data table (Joslin, weight variation in diabetics by age at onset) that is low-resolution in the source; some values are not fully legible.

Prevalence

  • 20–25% of the world’s population meets the definition for metabolic syndrome (Eckel et al., 2005).
  • ~60% of North American women aged 45–49; ~45% of North American men aged 45–49.
  • Prevalence varies substantially by country.
  • Prevalence increases with age: e.g. in French adults, <10% aged 30–60 rises to 18% aged 60–65; in Iranian adults, <10% aged 20–29 rises to 38% (men) and 67% (women) aged 60–69.
  • Individual components of metabolic syndrome are common in the general population (NHANES 2003–2006 data, approximate figures): elevated waist circumference ~46% men/~61% women; elevated TG ~36% men/~26% women; low HDL-C ~23% men/~28% women; elevated BP ~31% men/~29% women; elevated glucose ~46% men/~31% women (glucose figure includes known diabetics).

Slide 12's country/age comparison bar chart (India, Iran, Oman, Finland, Ireland, Scotland, Turkey, Australia, France, and several USA subgroups) was not numerically labelled on the original chart; the percentages recorded in the source transcript are visual estimates, not exact figures.

Why Metabolic Syndrome Matters

Identifying metabolic syndrome helps flag people at risk of serious medical conditions and supports increased monitoring, therapeutic intervention, and family screening.

In patients with metabolic syndrome:

  • Risk of type 2 diabetes is increased 5x (IDF, 2006).
  • 3.2 million annual deaths from diabetes worldwide; in high-incidence countries, one in four deaths aged 35–64 is due to diabetes.
  • Global healthcare cost of diabetes is ~$286 billion annually (15% of the global healthcare budget).
  • All-cause mortality risk ~1.4x (DECODE study, European).
  • Cardiovascular disease death risk: 2.26x (men), 2.78x (women) (DECODE study).
  • Cardiovascular disease risk 2–5x (Verona Diabetes Complications study).
  • 3x as likely to have a myocardial infarction or stroke (IDF, 2006).

Problems and Controversies with the Definition

  • The individual elements of metabolic syndrome are already very common in the population on their own.
  • Some already-established disease features are listed within some definitions as criteria — several alternate definitions essentially include type 2 diabetes as a criterion. If almost everyone diagnosed with metabolic syndrome already has type 2 diabetes because it is built into the definition, the diagnosis becomes less useful for identifying an at-risk population before disease develops.
  • Central obesity is a problematic risk factor: it combines intra-abdominal (“visceral”) and subcutaneous fat. Visceral fat is thought to matter more for risk, but requires imaging to measure accurately, which is impractical in routine practice. Average waist circumference also varies by ethnicity — partly addressed by the “harmonizing” definition’s ethnicity-specific cut-offs.
  • BMI and waist circumference are imperfect proxies for risk:
    • Two women with near-identical BMI, weight, and body fat mass can have very different visceral adipose tissue (VAT) area and visceral adipocyte size — in the example given, waist circumference tracked with VAT area (37 cm² vs 133 cm²) even though BMI and total body fat mass were similar between the two patients (Neeland et al., 2024).
    • Two individuals can share an identical waist circumference (102 cm) but have markedly different BMI (26 vs 32 kg/m²) and body composition. Assessing risk from BMI alone would wrongly rank the higher-BMI individual as higher risk; combining waist circumference with BMI instead reveals the lower-BMI individual has sarcopenia and visceral obesity (high cardiometabolic risk), while the higher-BMI individual has more subcutaneous fat and muscle mass (lower cardiometabolic risk).

Pathophysiology

Insulin resistance:

  • Hyperinsulinaemia predates diabetes mellitus.
  • Possible causes: elevated free fatty acids (FFAs) driving an inflammatory state; altered phosphorylation via SOCS (suppressor of cytokine signalling); AGE and RAGE (advanced glycation end-products and their receptor); and reactive oxygen species (ROS).
  • Leads to accumulation of fat in organs, with resultant inflammation and ongoing tissue damage, leading to diabetes, cardiovascular disease, hypertension, etc.

Pro-inflammatory cytokines:

  • Produced by expanded adipose tissue infiltrated by macrophages.
  • Increased: IL-6, IL-8, CRP, MCP-1, TNF-α. Decreased: adiponectin.
  • Trigger is uncertain — possibly genetics, oxidative stress, adipocyte necrosis, or FFAs.

Obesity as a state of chronic mild inflammation (Wellen & Hotamisligil, 2003) — staged progression with weight gain:

  1. Baseline: isolated preadipocytes and adipocytes.
  2. With weight gain: adipocytes enlarge and produce TNF-α and MCP-1; endothelial cells show physical stress/oxidative damage and release FFA; leptin and VEGF drive angiogenesis; a macrophage is recruited via MCP-1.
  3. With further weight gain: multiple macrophages form “crown-like” structures around/infiltrating enlarged adipocytes, producing IL-6, IL-1β, TNF-α and MCP-1, which drive JNK/NF-κB signalling and lead to insulin resistance.

Cross-organ effects of expanded adipose tissue (Harrison’s, 19th ed.) — adipose tissue releases FFA, TNF-α and IL-6 that act on:

  • Liver: ↓HDL cholesterol, ↑LDL particle number (via VLDL/apoC-III/apoB-100/TG); also increased CRP and fibrinogen → increased PAI-1 → a prothrombotic state.
  • Muscle: ↓glycogen, ↑triglyceride/lipid droplet accumulation, ↓CO2 production; receives FFA and insulin; adiponectin acts inhibitory on this pathway.
  • Pancreas: produces insulin.
  • Vasculature: hypertension, driven by increased sympathetic nervous system (SNS) activity, FFA, insulin and cytokines.
  • A central glucose signal connects liver, muscle and pancreas; adiponectin has inhibitory effects on the liver/muscle pathways.

Integrated mechanism (Neeland et al., 2024) — starting from abdominal obesity and adipose tissue insulin resistance, three parallel branches feed the liver, muscle and pancreas:

  • ↑ pro-inflammatory adipokine secretion (↑MCP-1, ↑IL-6, ↑TNF, ↑TGF-β, ↑leptin, ↑PAI-1) → chronic inflammation.
  • ↓ anti-inflammatory adipokine secretion (↓adiponectin, ↓IL-1 as shown).
  • ↑ lipolysis → ↑FFA.

The liver additionally contributes ↑fibrinogen, ↑uric acid and ↑hepatokines (↑CRP, ↑fetuin A, ↓FGF21) that feed back into chronic inflammation. Liver, muscle and pancreas together drive hepatic and peripheral insulin resistance and β-cell dysfunction, which branches into:

  • MASLD (metabolic dysfunction-associated steatotic liver disease), via lipotoxicity (↑ceramides, ↑DAG, ↑LDL, ↑de novo lipogenesis, ↑ROS, ↑oxidative stress, ↓mitochondrial function, ↓HDL) → hyperlipidaemia.
  • Type 2 diabetes mellitus, via glucotoxicity (↑AGE, ↑ROS, ↑oxidative stress, ↑gluconeogenesis, ↑uric acid, ↓mitochondrial function) → hyperglycaemia.

Hyperlipidaemia and hyperglycaemia both converge on the heart, kidney and blood vessels, producing atherosclerosis, endothelial dysfunction and increased cardiorenal risk (cardiovascular disease).

Overall progression model (Fig. 1) [slide does not cite a source for this figure]: a sensitive genotype, together with metabolic stress and inflammation, predisposes to obesity, which progresses sequentially through insulin resistance → glucose intolerance → metabolic syndrome → type 2 diabetes mellitus. This represents both a temporal/phenotypic progression and an underlying molecular-mechanism axis.

Other Conditions Associated with Metabolic Syndrome

  • Renal disease
  • NAFLD, NASH — now reclassified as MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis)
  • Polycystic ovarian syndrome (PCOS)
  • Obstructive sleep apnoea (OSA)
  • All may be tied to inflammation and insulin resistance.

CKM syndrome (Cardiovascular-Kidney-Metabolic):

  • Introduced in 2023 by the American Heart Association.
  • Encompasses: metabolic syndrome, diabetes mellitus, cardiovascular disease, and chronic kidney disease (CKD).
  • Late-stage additions: PCOS, OSA.

Management of Metabolic Syndrome

More evidence-based work is needed in this area; detailed clinical management approaches are deferred to the clinicians' lectures.

First steps:

  • Weight loss >5%.
  • Diet: decrease saturated fats; adherence to a diet matters more than the specific diet chosen; increase fruit, vegetables, grains, and fibre intake (>15 g/day).
  • Increase physical activity: at least 30 min/day (walking, jogging, swimming, biking, sports); sustaining activity is important for maintaining any weight loss.
    (Tuomilehto et al., 2001; Eckel et al., 2005)

Evidence for intervention: the STENO-2 study combined lifestyle change, glucose control, RAAS inhibition, aspirin, and lipid lowering, producing a 46% decrease in death risk and a 57% decrease in cardiovascular death risk.

Pharmacotherapy — candidate agent classes and their effects on metabolic syndrome components (Neeland et al., 2024):

ClassEffects on MetS componentsStrengthsLimitationsExample medications
GLP-1RA / GLP-1-based therapy↓↓ abdominal obesity, ↓↓ glucose/IR, ↓↓ TGs, ↑HDL-C, ↓BP, ↓inflammation, ↓↓ hepatic steatosisCV benefit mainly in ASCVD; kidney benefitGI adverse eventsLiraglutide, exenatide, lixisenatide, dulaglutide, efpeglenatide, semaglutide, tirzepatide, orforglipron, survodutide, retatrutide, cafraglutide
SGLT2 inhibitors↓ abdominal obesity, ↓glucose, ↓TGs, ↑HDL-C, ↓BP, ↓inflammation, ↓hepatic steatosisCV benefit mainly in heart failure; kidney benefit↑genital tract infection, volume depletion, ketosisDapagliflozin, empagliflozin, canagliflozin, ipragliflozin, enavogliflozin
DPP-4 inhibitors–abdominal obesity, ↓glucose, ↓TGs, –HDL-C, –BP, ↓inflammation, –hepatic steatosisAlbuminuria reduction↑heart failure risk with saxagliptinSitagliptin, vildagliptin, linagliptin, alogliptin, saxagliptin, teneligliptin, gemigliptin, evogliptin
TZDs↑abdominal obesity, ↓↓glucose, ↓↓TGs, ↑HDL-C, –BP, ↓↓inflammationCV benefit mainly in stroke↑heart failure risk, ↑osteoporosis riskPioglitazone, rosiglitazone, lobeglitazone
Statins–abdominal obesity, slightly ↑glucose, ↓TGs, –HDL-C, –BP, ↓inflammation, –hepatic steatosisCV benefitMuscle-related side effects, glucose dysregulation, ↑LFTsAtorvastatin, rosuvastatin, simvastatin, fluvastatin, pravastatin, lovastatin, pitavastatin
Fibrates–abdominal obesity, slightly ↓glucose, ↓↓TGs, ↑HDL-C, –BP, ↓inflammation↓diabetic microvascular complicationsTransient ↓eGFRFenofibrate, gemfibrozil
EPA–abdominal obesity, slightly ↓glucose, ↓↓TGs, ↑HDL-C, –BP, ↓inflammationCV benefitAtrial fibrillation at high dose, GI adverse eventsIcosapent ethyl
ARB / ACEi–abdominal obesity, slightly ↓glucose, –TGs, –HDL-C, ↓↓BP, ↓inflammationCV benefit; kidney benefitCough with ACEiLosartan, candesartan, telmisartan, irbesartan, eprosartan, fimasartan, olmesartan, azilsartan

Surgery: bariatric surgery gives good results — 95% of patients had no metabolic syndrome one year after surgery (Eckel et al., 2005). Whether GLP-1 agonists and similar agents will achieve comparable benefit is an open question raised in the lecture.

Self-test

Definition

  1. State the IDF (2006, updated 2009) diagnostic criteria for metabolic syndrome.
  2. What BMI value allows central adiposity to be assumed under the IDF definition, without a specific waist measurement?
  3. State the WHO (1998) diagnostic criteria for metabolic syndrome.
  4. Give the five components and cut-points of the 2009 “harmonized” criteria.
  5. Why do harmonized definitions use ethnicity/region-specific waist-circumference cut-offs?

History

  1. List, in chronological order, four milestones in the history of the metabolic syndrome concept, with the researcher/year for each.
  2. Who coined the term “Syndrome X”, in what year, and what six features did it comprise?
  3. What is the CKM syndrome, and when and by whom was it introduced?

Prevalence

  1. What proportion of the world’s population meets the definition for metabolic syndrome?
  2. How does the prevalence of metabolic syndrome change with age? Give one specific example with figures.
  3. Which single component of metabolic syndrome is most prevalent, and how does its prevalence differ between men and women (approximate NHANES figures)?

Clinical importance

  1. By how much does metabolic syndrome increase the risk of type 2 diabetes?
  2. Give three statistics illustrating the increased cardiovascular risk associated with metabolic syndrome.
  3. A patient is newly found to meet criteria for metabolic syndrome. What three clinical actions might this prompt?

Problems with the definition

  1. Explain why including type 2 diabetes as a diagnostic criterion for metabolic syndrome undermines the definition’s clinical usefulness.
  2. Why is central obesity considered a problematic risk factor to define and measure?
  3. Two patients have near-identical BMI and body fat mass but different waist circumferences. What does this indicate about visceral adipose tissue, and why does it matter?
  4. Two individuals share an identical waist circumference but different BMI. Explain why assessing cardiometabolic risk from BMI alone would give the wrong answer here.

Pathophysiology

  1. List three possible causes of insulin resistance given in the lecture.
  2. What is the downstream consequence of insulin resistance, according to the lecture?
  3. List the pro-inflammatory cytokines/markers increased in expanded, macrophage-infiltrated adipose tissue, and the one adipokine that is decreased.
  4. Describe the three-stage progression by which obesity produces chronic inflammation (Wellen & Hotamisligil model).
  5. Describe how expanded adipose tissue affects the liver, muscle, pancreas and vasculature to produce the features of metabolic syndrome.
  6. Distinguish the mechanism by which chronic hyperglycaemia contributes to disease (glucotoxicity) from the mechanism by which chronic hyperlipidaemia contributes to disease (lipotoxicity), as presented in the integrated pathophysiology model.
  7. Close the note. From memory, trace the pathway from abdominal obesity/adipose tissue insulin resistance through to increased cardiorenal risk, then check against the Pathophysiology section above.

Associated conditions and management

  1. List four conditions, other than diabetes and cardiovascular disease, associated with metabolic syndrome.
  2. What are the first-line, non-pharmacological steps in managing metabolic syndrome?
  3. What were the components of the STENO-2 intervention, and what were its two headline outcomes?
  4. Name one drug class from the lecture that reduces abdominal obesity, glucose/insulin resistance, triglycerides and hepatic steatosis, and give two example medications.
  5. What outcome was reported for bariatric surgery in relation to metabolic syndrome resolution?

Answers

Graph View

Backlinks